PT - JOURNAL ARTICLE AU - Chen, Fei AU - Darst, Burcu F AU - Madduri, Ravi K AU - Rodriguez, Alex A AU - Sheng, Xin AU - Rentsch, Christopher T AU - Andrews, Caroline AU - Tang, Wei AU - Kibel, Adam S AU - Plym, Anna AU - Cho, Kelly AU - Jalloh, Mohamed AU - Gueye, Serigne Magueye AU - Niang, Lamine AU - Ogunbiyi, Olufemi AU - Popoola, Olufemi AU - Adebiyi, Akindele O. AU - Aisuodionoe-Shadrach, Oseremen I. AU - Ajibola, Hafees O AU - Jamda, Mustapha A AU - Oluwole, Olabode P AU - Nwegbu, Maxwell AU - Adusei, Ben AU - Mante, Sunny AU - Darkwa-Abrahams, Afua AU - Mensah, James E. AU - Adjei, Andrew Anthony AU - Diop, Halimatou AU - Lachance, Joseph AU - Rebbeck, Timothy R AU - Ambs, Stefan AU - Gaziano, J. Michael AU - Justice, Amy C AU - Conti, David V AU - Haiman, Christopher A AU - the VA Million Veteran Program TI - Validation of a Multi-ancestry Polygenic Risk Score and Age-Specific Risks of Prostate Cancer: A Meta-analysis Within Diverse Populations AID - 10.1101/2022.05.03.22274606 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.03.22274606 4099 - http://medrxiv.org/content/early/2022/05/03/2022.05.03.22274606.short 4100 - http://medrxiv.org/content/early/2022/05/03/2022.05.03.22274606.full AB - Background We recently developed a multi-ancestry polygenic risk score (PRS) that effectively stratifies prostate cancer risk across populations. In this study, we validated the performance of the PRS in the multi-ancestry Million Veteran Program (MVP) and additional independent studies.Methods Within each ancestry population, the association of PRS with prostate cancer risk was evaluated separately in each case-control study and then combined in a fixed-effects inverse-variance-weighted meta-analysis. We further assessed the effect modification by age and estimated the age-specific absolute risk of prostate cancer for each ancestry population.Results The PRS was evaluated in 31,925 cases and 490,507 controls, including men from European (22,049 cases, 414,249 controls), African (8,794 cases, 55,657 controls), and Hispanic (1,082 cases, 20,601 controls) populations. Comparing men in the top decile (90-100% of the PRS) to the average 40-60% PRS category, the prostate cancer OR was increased 3.8-fold in European ancestry men (95% CI=3.62-3.96), 2.8-fold in African ancestry men (95% CI=2.59-3.03), and 3.2-fold in Hispanic men (95% CI=2.64-3.92). The PRS did not discriminate risk of aggressive versus non-aggressive prostate cancer. However, the OR diminished with advancing age (European ancestry men in the top decile: ≤55 years, OR=7.11; 55-60 years, OR=4.26; >70 years, OR=2.79). Men in the top PRS decile reached 5% absolute prostate cancer risk ∼10 years younger than men in the 40-60% PRS category.Conclusions Our findings validate the multi-ancestry PRS as an effective prostate cancer risk stratification tool across populations. A clinical study of PRS is warranted to determine if the PRS could be used for risk-stratified screening and early detection.Funding This work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U19 CA214253 to C.A.H., U01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., K99 CA246063 to B.F.D, and T32CA229110 to F.C), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), the Achievement Rewards for College Scientists Foundation Los Angeles Founder Chapter to B.F.D, and the Million Veteran Program-MVP017. This research has been conducted using the UK Biobank Resource under application number 42195. This research is based on data from the Million Veteran Program, Office of Research and Development, and the Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers U19 CA214253 to C.A.H., U01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., K99 CA246063 to B.F.D, and T32CA229110 to F.C), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), the Achievement Rewards for College Scientists Foundation Los Angeles Founder Chapter to B.F.D, and the Million Veteran Program-MVP017. This research has been conducted using the UK Biobank Resource under application number 42195. This research is based on data from the Million Veteran Program, Office of Research and Development and the Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols were approved by each site's Institutional Review Board in accordance with the principles outlined in the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThis investigation included published results from the following studies under DOI numbers 10.1038/s41588-020-00748-0 and 10.1093/jnci/djab058. The MVP individual level data is available to approved VA researchers through standard mechanisms. Full GWAS summary statistics can be found in dbGaP (https://www.ncbi.nlm.nih.gov/gap/) under the MVP accession (phs001672).Publicly available data described in this manuscript can be found from the following websites: 1000 Genomes Project (https://www.internationalgenome.org/); SEER (https://seer.cancer.gov/); National Center for Health Statistics, and CDC (https://www.cdc.gov/nchs/index.htm).